Table 13.
Other conditions
| Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator* | Outcomes | Conclusions from data | AMSTAR-2 rating |
|---|---|---|---|---|---|---|---|---|
| Huntley, 2000 [66] | Inception to Dec 1999; 4 | NR | 1 | Asthma |
I: Plant-derived cannabinoids C: Placebo |
• Airway resistance (raw) | Only one study included | M |
| Singh, 2007 [77] | Inception to Dec 2004; 6 | Non-profit | 4 | Asthma |
I: Plant-based cannabis C: Placebo; isoproterenol; low-dose marijuana |
• Pulmonary function test | Reported SBS | M |
| Snedecor, 2013 [70] | To Jun 2011; 5 | Industry | 1 | Diabetes |
I: Plant-derived cannabinoids C: placebo |
• Peripheral NP (mean reduction in pain) • Peripheral NP (mean probability of 30% pain reduction) |
Unclear efficacy (not enough information provided by authors) | L |
| Norton, 2017 [28] | Inception–Feb 2016; 5 | NR | 3 | Inflammatory bowel disease |
I: Plant-based cannabis C: No comparator (observational study) |
N/A observational data | N/A observational data | CL |
| Langhorst, 2015 [44] | Inception–Mar 12, 2014; 4 | Non-profit | 1 | Inflammatory bowel disease (Crohn's, ulcerative colitis, IBS) |
I: Plant-based cannabis C: Placebo cigarettes (THC removed) |
• Response rate • QoL • Remission rate |
Only one study included | M |
| CADTH, 2014 [81] | Jan 1, 1982 to Aug 8 2014; 5 | NR | 4 | Nausea and vomiting (non-chemotherapy-induced) |
I: Synthetic cannabinoids C: Metoclopramide |
• Postoperative nausea and vomiting • Patient rating of nausea and vomiting (VAS) |
Only one study included | L |
CADTH Canadian Agency for Drugs and Technologies in Health, IBS irritable bowel syndrome, NR not reported, QoL quality of life, SBS study-by-study, VAS visual analog scale
*A colon indicates that there were separate analyses for each comparator